ORIGINAL PAPER

WILEY

The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study

Aminah Almurjan | Hannah Macfarlane | Raj K. S. Badhan

Medicines Optimisation Research Group, Aston Pharmacy School, Aston University, Birmingham, UK

Correspondence
Raj K. S. Badhan, Aston Pharmacy School, Life and Health Sciences, Aston University, Birmingham B4 7ET, UK.
Email: r.k.s.badhan@aston.ac.uk

Funding information
Kuwait University

Abstract

Sertraline is known to undergo changes in pharmacokinetics during pregnancy. CYP 2C19 has been implicated in the interindividual variation in clinical effect associated with sertraline activity. However, knowledge of suitable dose titrations during pregnancy and within CYP 2C19 phenotypes is lacking. A pharmacokinetic modeling virtual clinical trials approach was implemented to: (i) assess gestational changes in sertraline trough plasma concentrations for CYP 2C19 phenotypes, and (ii) identify appropriate dose titration strategies to stabilize sertraline levels within a defined therapeutic range throughout gestation. Sertraline trough plasma concentrations decreased throughout gestation, with maternal volume expansion and reduction in plasma albumin being identified as possible causative reasons. All CYP 2C19 phenotypes required a dose increase throughout gestation. For extensive metabolizer (EM) and ultrarapid metabolizer (UM) phenotypes, doses of 100–150 mg daily are required throughout gestation. For poor metabolizers (PM), 50 mg daily during trimester 1 followed by a dose of 100 mg daily in trimesters 2 and 3 are required.

KEYWORDS
PBPK, pharmacokinetics, phenotype, pregnancy, sertraline

1 | INTRODUCTION

Depression throughout pregnancy is known to affect up to 20% of women (Fisher et al., 2012; Vigod et al., 2016), although fewer than 20% of pregnant women will actually receive suitable treatment (Byatt et al., 2016; Geier et al., 2015). The risk of untreated depression is particularly important given that death associated with suicide can affect one in every 25 women aged 20–35 years, from conception through to the postnatal period (J. J. Kim & Silver, 2016).

In addition, antenatal depression is a major risk factor for developing postnatal depression (McAllister-Williams et al., 2017). A key strategy in the management of moderate-to-severe depression is the use of selective serotonin reuptake inhibitors (SSRIs) as first-line agents and which include sertraline, citalopram, fluoxetine, paroxetine, and fluvoxamine.

Sertraline is one of the most frequently used SSRIs globally, particularly during pregnancy (Bérard et al., 2017; Colvin et al., 2011; Nordeng et al., 2012; Oberlander et al., 2008; Ramos et al., 2007;

Reis & Källén, 2010; Zakiyah et al., 2018), and is commonly used to manage, among others, anxiety and panic disorders and obsessive–compulsive disorders (Pae & Patkar, 2007; Westin et al., 2017). Furthermore, SSRIs have been demonstrated to lead to very few birth defects (Byatt et al., 2013).

Sertraline is metabolized by multiple Cytochrome P450 enzymes, including primarily CYP 2C19 and 2B6 (Saiz-Rodríguez et al., 2018) along with contributions from CYP 2C9, CYP 2D6, and CYP 3A4 (Obach et al., 2005) and is a moderate inhibitor of CYP 2D6 (Alfaro et al., 2000; Lam et al., 2002). Confounding the use of sertraline in pregnancy are the longitudinal changes in CYP isozyme expression during gestation, where expression increases for 2B6 (Koh et al., 2012), 2D6 (Högstedt et al., 1985; Högstedt et al., 1983; Wadelius et al., 1997), and 3A4 (Kosel et al., 2003; Prevost et al., 1992) and decreases for 2C19 (McGready, Stepniewska, Edstein, et al., 2003; McGready, Stepniewska, Seaton, et al., 2003; Ward et al., 1991).

The implications of such changes during gestation make dose optimization challenging, and this is confounded by the paucity of the pharmacokinetic studies for sertraline use during pregnancy. In those that have reported plasma concentrations during gestation, conflicting results indicate either an increase in trough plasma levels (Westin et al., 2017), necessitating possible dose reduction, or a decrease in plasma concentrations, requiring a possible dose increase (M.P. Freeman et al., 2008; Hostetter et al., 2000; D.K. Sit, et al 2008). The conflicting reports may, in part, be due to the complex metabolism route and longitudinal changes in the abundance of these enzyme pathways during gestation, and often small sample (patient) sizes within studies. Nevertheless, the consensus within all of these studies highlights the need for careful monitoring of depressive symptoms during the perinatal period.

Furthermore, CYP 2C19 is highly polymorphic and these genetic variabilities have been implicated in the requirement for dose adjustment in the use of sertraline and other SSRIs with phenotypes of CYP 2C19 (Bråten et al., 2020; Hicks et al., 2015). Over 30 allelic variants have been identified for CYP 2C19, with the majority of patients being carriers of CYP 2C19 *1 (extensive metabolizer [EM] trait), *2 (poor metabolizer [PM] trait), or *17 (ultrarapid metabolizer [UM] trait) alleles. Further, guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) (https://cpicpgx.org) detail the allele definitions and phenotypic interpretations of CYP 2C19 and their clinical relevance alongside providing recommendations for genotype-guided dosing of sertraline, namely, advocating a dose increase of at least 50% in PM but no dose adjustment for UM phenotype patients. However, conflicting reports on the impact of specific CYP 2C19 genotypes/phenotypes on sertraline have highlighted the need to investigate the impact of this further on dose adjustments (Bråten et al., 2020).

In the context of the postnatal period, SSRIs have been reported to lead to Post Natal Adaptation Syndrome (PNAS). This is, in part, due to their ability to cross the placenta, which may result in increased serotonin concentrations in the developing fetus, thus: impacting fetal respiratory, cardiovascular, and neurological

development (Bérard et al., 2017; Byatt, Deligiannidis, & Freeman, 2013; Zakiyah et al., 2018).

A recent study implemented a pharmacokinetic modeling approach to explore the changes in sertraline concentrations through gestation (George et al., 2020). While they also simulated a decrease in sertraline levels, their study lacked both the use of a full-body physiological model with a dedicated gestational-age dynamic fetal model and used a limited dataset for validation purposes. Given the limited pharmacokinetic data throughout pregnancy, the predominantly reported decrease in sertraline concentrations, coupled with its complex elimination pathways, we have applied, for the first time, a full-body virtual clinical trials pharmacokinetic model to assess the dosing of sertraline throughout gestation to identity necessary dose titrations.

With a focus on the existing guidelines for the use of sertraline in CYP 2C19 phenotypes, the primary aim of this study was to: (i) evaluate the influence of gestation on plasma sertraline levels, and (ii) provide a clinically relevant dosing titration strategy for CYP 2C19 phenotype status during gestation.

2 | MATERIALS AND METHODS

We utilized the Simcyp Simulator, a physiologically-based pharmacokinetic (PBPK) modeling tool, to conduct virtual clinical trials simulations (Simcyp, a Certara company, Sheffield, UK, v. 17). Unless otherwise stated, we incorporated mixed genders (50:50) into all simulations. We utilized a four-stage workflow (Figure 1).

2.1 | Step 1: Validation of sertraline

We utilized the Simcyp "healthy volunteer" (HV) population group for studies with baseline populations consisting of nonpregnant females. For pregnant population groups we used the Simcyp "pregnancy" population. This population was developed previously by Simcyp researchers and includes gestation-dependent changes in physiology, cardiac output, tissue perfusion, blood volume alongside biochemistry modification (e.g., human serum albumin) and enzyme/protein expression (Abduljalil et al., 2012; De Sousa Mendes et al., 2015; Jogiraju et al., 2017; Lu et al., 2012). Sertraline is not available within the Simcyp Simulator; however, a previous study developed and validated a sertraline compound for use within the Simcyp Simulator (Templeton et al., 2016), with modifications made by our group to allow its use during gestation.

In order to apply this previously validated model within the context of our studies, five retrospective clinical studies were employed, four single-dose studies and one multiple-dose study: (i) 24 healthy adults (12 male and 12 female) aged between 18 and 45 years old dosed with a single-oral dose of 50 mg sertraline (Niyomnaitham et al., 2009); (ii) 18 healthy subjects administered a single 50 mg oral dose of sertraline (X. Chen, et al., 2006, pp. 2483–2489); (iii) five healthy male volunteers, mean age 26.1 years ± 4.2 years, administered a 50 mg single dose of sertraline (K.M. Kim et al., 2002);

FIGURE 1 A workflow modeling approach for sertraline

(iv) five male and five female (19–31 years) dosed 100, 200, and 400 mg as a single dose with C_{max} reported (Saletu, Grunberger, & Linzmayer, 1986); and (v) 11 male and 11 female healthy volunteers aged between 18 and 45 years old administered a 200 mg daily for 30 days, with sampling on day 30 (Ronfeld et al., 1997); The design of trials within Simcyp were matched to these clinical studies. Simcyp Simulator parameters for sertraline are detailed in the Supplementary Materials (Section 1: Table S1).

2.2 | Step 2: Validation of sertraline during pregnancy

In order to apply the developed sertraline model during pregnancy, we conducted further validation using data extracted from a retrospective analysis of therapeutic drug monitoring services in Norway (Westin et al., 2017). This study included 56 pregnant and 52 nonpregnant (female) sertraline plasma concentrations, obtained from 34 women taking an oral dose of 50 mg daily. Importantly, this study reported individualized sample data throughout gestation rather than a central tendency without variance (D.K. Sit et al., 2008), missing patient sample data throughout the study or poor sample sizes (M.P. Freeman et al., 2008).

The Simcyp Pregnancy model has been utilized previously to assess changes in plasma concentration in pregnant women (Jogiraju et al., 2017; Ke et al., 2018; Olafuyi & Badhan, 2019) and this study represents its application in the context of sertraline for the first time. The Simcyp Pregnancy model changes the physiology of the mother (e.g., tissue volumes) throughout the study period, which allows the model to operate in a dynamic nature, updating the prediction of the volume of distribution at steady-state (Vss) through the study as a result of updated estimates of the tissue-partition coefficient (Kp), as opposed to using fixed estimates of Kp and Vss.

The Simcyp Pregnancy model does not inherently include longitudinal changes in CYPs 2C19 and 2B6, and these were incorporated based on previous reports of successful implementation within the Simcyp Simulator (Almurjan et al., 2020; Ke et al., 2018) (Supplementary Materials (Section 2). In order to replicate the study by Westin et al. (2017), we utilized a 38-weeks' gestation and a 10 × 10 (n = 100 subjects) study design with sertraline doses of 50 mg daily.

Data were collected for every 5th week and presented as the final 24 h of that period. A similar trial design was implemented for nonpregnant females (baseline).

2.3 | Step 3: Impact of CYP 2C19 polymorphism on sertraline plasma concentration during pregnancy

Sertraline plasma concentrations are known to be altered in different CYP 2C19 phenotypes (Hicks et al., 2015). In order to simulate the impact of CYP 2C19 phenotypes in pregnant women, we simulated entirely extensive metabolizer (EM), poor metabolizer (PM), and ultrarapid metabolizer (UM) populations through revision of the default phenotype distribution to ensure uniform phenotype populations. For each phenotype, CYP 2C19 enzyme abundance was also incorporated and detailed in the Supplementary Materials (Section 2).

The study design implemented a 10 × 10 trial design with a daily dose of 50 mg once-daily throughout gestation and sampling (of plasma concentration) conducted for every 5th week and presented as the final 24 h of that period. Where appropriate, data were also presented on the final dosing day of the week during trimester 1 (T1: week 10), trimester 2 (T2: week 20), and trimester 3 (T3: week 30).

In the absence of any published data, the default value of 0 pmol/mg was used for CYP 2C19 PM phenotypes within the Simcyp Simulator (Djebli et al., 2015; Gong et al., 2018).

## 2.4 | Step 4: Dose adjustment during gestation

To explore approaches to sertraline dose titration during gestation on resultant plasma concentrations, dosing was initiated at 50 mg once-daily and increased in weekly increments by 50 mg to a maximum of 300 mg once-daily. A proposed therapeutic range was set at 10–75 ng/ml (Bråten et al., 2020). This was based on reports from the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie' (AGNP) suggesting a range of 30–500 nM (Hiemke et al., 2018), equating to a lower limit of ~10 ng/ml. The upper limited was defined by Bråten et al. in relation to the concentration of sertraline occurring the serotonin transporter (SERT) and being approximately 250 nM (~75 ng/ml) (Bråten et al., 2020; Mauri et al., 2003).

Data were reported for each phenotype studied, namely, EM, PM, and UM subjects, on the final day of each trimester and presented as the percentage of subjects possessing trough plasma concentrations outside of the therapeutic range (i.e., below 10 ng/ml and above 75 ng/ml).

2.5 | Predictive performance

To ensure appropriate predictive performance (Steps 1–2), predictions of pharmacokinetic metrics that were within 2-fold (0.5–2.0-fold) of published data was accepted as part of the "optimal" predictive performance (Edginton et al., 2006; Ginsberg et al., 2004; Parrott et al., 2011). Furthermore, predictions in Steps 1–2 were also validated using a visual predictive checking (VPC) strategy (U.S. Food and Drug Administration, 2012) when compared to reported data. This approach compared the Simcyp Simulator predicted concentration–time profiles, which consisted of either a mean or median and the 5th and 95th percentiles, against the observed data. A successful validation approach was assumed when Simcyp-predicted results overlapped with the observed datasets (Almurjan et al. 2020; Olafuyi & Badhan, 2019).

2.6 | Data and statistical analysis

Retrospective (observed) clinical data were extracted from reported studies using WebPlotDigitizer v. 3.10 (http://arohatgi.info/Web-PlotDigitizer/). Tabulated (observed) clinical data were utilized as reported in studies, namely, mean and standard deviation (Steps 1 and 2). Exploratory studies (Steps 3 and 4) were reported as median and range, unless otherwise stated. Statistical analysis was conducted using a nonparametric Kruskal–Wallis test with a Dunn's multiple comparison post-hoc test. Significance was confirmed with $p < 0.05$. All statistical testing was conducted using GraphPad Prism v. 8.00 for Windows (GraphPad Software, La Jolla, CA, www.graphpad.com).

3 | RESULTS

3.1 | Step 1: Validation of sertraline

A previously reported sertraline model (Templeton et al., 2016) was adapted, implementing a full-PBPK model in order to appropriately model physiological changes during gestation and their impact on Vss. The model was validated against four single-dose studies, one multiple-dose study, and a dose escalation study. The resulting predicted plasma concentration–time profiles successfully predicted

FIGURE 2 Simulated sertraline plasma concentrations. (a) Single 50 mg oral doses of sertraline (X. Chen, Duan, et al., 2006, pp. 2483–2489; K.M. Kim et al., 2002; Niyomnaitham et al., 2009); (b) Multiple daily 50 mg oral doses reported on day 30 (Ronfeld et al., 1997) for males (red) and females (green); (c) 100, 200, and 400 mg single doses of sertraline (Saletu et al., 1986); (d) Forest plot showing the predicted mean ± SD over the observed ratio of pharmacokinetic parameters in subjects, with the dotted and shaded area representing the 2-fold range (0.5–2) and solid black line the line of unity. For (a) and (b), solid circles represent observed clinical data with error bars indicating standard deviation, solid lines represent predicted mean concentration–time profile, and the 5th and 95th percentile range represented by dotted lines. For (c), solid red circles represent observed clinical data, with upper and lower red lines indicating standard deviation. The solid black square and error bars indicate mean and standard deviation, respectively

single-dose (Figure 2a), multiple-dose (Figure 2b), and dose escalation studies (Figure 2c). Furthermore, the resultant Simcyp predicted t_{max}, C_{max}, and area under the curve (AUC) were within 2-fold of the reported values (Figure 2d) (See Supplementary Materials Section 3: Table S1).

3.2 | Step 2: Validation of sertraline during pregnancy

The distribution of simulated sertraline plasma concentrations was similar to the range of observations reported (Westin et al., 2017) during pregnancy (Figure 3). The predicted mean plasma concentration in nonpregnant females (baseline), 16.20 ng/ml $\pm$ 10.32 ng/ml, was within 2-fold of that reported, 11.1 ng/ml $\pm$ 7.02 ng/ml (Westin et al., 2017). Further, when compared to baseline plasma concentrations decreased for trimester 2 (week 15: 16.13 ng/ml $\pm$ 9.71 ng/ml, week 20: 15.01 ng/ml $\pm$ 9 ng/ml) and trimester 3 (week 30: 14.41 ng/ml $\pm$ 8.59 ng/ml, week 35, 13.68 ng/ml $\pm$ 8.13 ng/ml). The decrease from baseline was only statistically significant for week 35 ($p = 0.021$).

Predicted concentrations were obtained from subjects ($n = 100$) administered a 50-mg daily dose and data collected as postdose (trough concentrations) sampled on the final 24-h period after dosing and collated every 5 weeks (black open circles). Sertraline concentrations in nonpregnant female are illustrated as "Baseline." Red open circles represent pooled (observed) plasma concentrations obtained from a total of 34 subjects. The therapeutic window is represented by the shaded regions between 10 ng/ml to 75 ng/ml. Blue horizontal lines represent mean plasma concentration for the simulated dataset.

3.3 | Step 3: Impact of CYP 2C19 polymorphism on sertraline plasma concentrations during pregnancy

CYP 2C19 is highly polymorphic and the primary metabolic pathway for sertraline. Changes in trough concentrations and intrinsic clearance (Clint) was assessed for baseline and during gestation for CYP

2C19 phenotype subjects, using frequencies reported within Simcyp Simulator (EM: 59%, PM: 9.2%, and UM: 31.8%).

The median trough plasma concentration decreased by 17.2% (EM, $p < 0.001$), 14.4% (PM, $p < 0.05$), and 20% (UM, $p < 0.001$) by week 30 when compared to baseline (Figure 4) (Supplementary Materials: Section 3 Table S2).

The impact of pregnancy on sertraline trough (C_{min}) plasma concentrations for CYP 2C19 EM and UM in nonpregnant females (baseline) and throughout pregnancy following a 50-mg once-daily dose to 100 subjects per phenotype. Data represented by box-and-whisker plots with median, 5th and 95th percentiles detailed. $^*p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$.

Despite decreases in trough plasma concentrations throughout gestation, CYP 2C19 Clint also decreased. For EMs, a decrease in the median Clint by CYP 2C19 was noticed from the 1st trimester (week 5: 78.4 L/h [17.5–611 L/h]) and continued to decrease in weeks 10 and 15: 68.5 L/h [13.8–533.8 L/h], 63.8 L/h [13.3–513.7 L/h], respectively, when compared to the baseline Clint, 78.4 L/h [17.5–622.1 L/h]. Statistically significant decreases in Clint were apparent from gestational week (GW) 20 onwards when compared to baseline subjects ($p < 0.05$) (Figure 5) (Supplementary Materials: Section 4 Table S3).

For UMs, a decrease in the median Clint by CYP 2C19 was also noticed from the 1st trimester (week 5: 97.5 L/h [21.7–721.6 L/h]) and continued to decrease in weeks 10 and 15, 90.4 L/h [20.1–671.7


FIGURE 4 Simulated sertraline trough plasma concentrations for CYP 2C19 polymorphs

FIGURE 3 Model predicted and observed plasma concentrations of sertraline throughout pregnancy


FIGURE 5 The impact of CYP 2C19 polymorphism on sertraline clearance throughout pregnancy

L/h] and 83.3 L/h [18.5–618.7 L/h], respectively, when compared to the baseline Clint, 105.17 L/h [24.5–776.3 L/h]. A statistically significant decrease in Clint was apparent from GW 20 onwards when compared to nonpregnant subjects ($p < 0.05$) (Figure 5) (Supplementary Materials: Section 4 Table S3).

The impact of CYP 2C19 on EM and UM phenotypes on Simcyp predicted sertraline in vivo intrinsic clearance for nonpregnant females (baseline) and during pregnancy, following a 50-mg once-daily dose to 100 subjects per phenotype. Data represented by box-and-whisker plots with median, 5th and 95th percentiles detailed. $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, $****p < 0.0001$.

3.4 | Step 4: Sertraline dose optimization

In order to address changes in sertraline concentrations during gestation for CYP 2C19 phenotype subjects, we quantified the percentage of subjects with plasma concentrations outside of the therapeutic range (i.e., below 10 ng/ml and above 75 ng/ml) across a dosing range of 50–300 mg daily.

Regardless of the phenotype, the daily sertraline dose required to maintain trough concentrations within the therapeutic window was above the usual 50 mg/day throughout pregnancy. When attempting to identify an optimal dose, we ensured a balance of a low percentages of subjects outside of this window, with an optimal dose defined as where no more than 20% of subjects possessed concentrations outside of the window (Figure 6) (Supplementary Materials: Section 5 Table S4).

For EM and UM, a dose of 100–150 mg daily is suggested to be optimal throughout pregnancy. For PM, a starting dose of 25 mg once-daily resulted in >60% of subjects with trough levels below 10 ng/ml across pregnancy (Figure 6). However, a dose of 50 mg once-daily resulted in 24% of subjects possessing trough levels below 10 ng/ml (Figure 6). During trimesters 2 and 3, an increase in dose to 100 mg once-daily resulted in less than 10% of the subjects demonstrating trough levels below 10 ng/ml (Figure 6) (Supplementary Materials: Section 5 Table S4).

Doses were titrated in increments of 50 mg every 3 days over a range of 50–300 mg once-daily throughout pregnancy. Trough plasma concentrations were reported for the final dosing day of each trimester in specific EM, PM, or UM pregnancy population groups. Percentages of subjects with plasma concentration (trough) outside of the therapeutic range (below 10 ng/ml [left panels] and above 75 ng/ml [right panels]) are reported.

4 | DISCUSSION

Depression is a leading cause of disability worldwide (World Health Organization, 2008), and is thought to affect more than 20% of pregnant women (Fisher et al., 2012; Gaynes et al., 2005; Vigod et al., 2016). A key challenge for healthcare professionals is the use of pharmacological interventions during pregnancy, which is often informed by balancing the expected benefits for the mother's mental health with the possible risks to the fetus. This decision is further complicated by gestational-related alterations in maternal physiology (Isoherranen & Thummel, 2013), which can impact the pharmacokinetics of drugs. Often the combined impact of these, in addition to the longitudinal nature of these alterations, makes it difficult to extrapolate their impact during clinical practice (Tracy et al., 2005). To augment the existing empirical approaches to treatment interventions, the application of robust and well-validated pharmacokinetic models offers a unique opportunity to apply virtual clinical trials to support medicine optimization in mental health for special population groups.

Sertraline is metabolized by multiple enzymes, including CYPs 2C19, 2B6, 2C9, 3A4, and 2D6. Confounding the use of sertraline in pregnancy is the gestational alterations in maternal CYP 2C19 activity, which has been determined to decrease by 62% and 68% during trimesters 2 and 3, respectively (McGready, Stepniewska, Edstein, et al., 2003; McGready, Stepniewska, Seaton, et al., 2003; Ward et al., 1991). Despite this decrease, several confounding studies have noticed either an apparent decrease (M.P. Freeman et al., 2008; Hostetter et al., 2000; D.K. Sit et al., 2008) or increase (Westin et al., 2017) in sertraline plasma concentrations during gestation.

In this study we applied virtual clinical trials dosing of sertraline throughout pregnancy, to identity suitable dose titration necessary to support therapeutically maintained sertraline plasma concentrations in the mother throughout pregnancy.

We adapted a previously published sertraline model (Templeton et al., 2016) to allow its use within the context of gestation, and this was fully validated with both single- and multiple-dose studies in both pregnant and nonpregnant subjects, with predictions to 2-fold of those reported (Figure 2) (Supplementary Materials: Section 3 Table S1) and spanning a similar range within the population studies (Figure 2). However, a wider AUC range in the predicted–observed ratios (Figure 2d), although still within 2-fold, are thought to be a reflection of the complexity associated with the metabolism of sertraline, namely, CYPs 2C9, 2C129, 2B6, 2D6, and 3A4, and hence the associated contribution towards interindividual variability. The variance in AUC from clinical studies (measured as mainly the standard deviation) was broadly similar to those simulated within our studies (See Supplementary Materials Section 3).

A recent report by Westin et al. (2017) highlighted sertraline plasma concentration throughout gestation in 34 subjects. This was used as the basis for validation of the pregnancy PBPK model. The resulting mean plasma concentrations in nonpregnant subjects (16.20 ng/ml ± 10.32 ng/ml) were within 2-fold of those reported (Westin et al., 2018) and also demonstrated a similar predicted range to that reported (Figure 3). Furthermore, we demonstrated a decrease in mean plasma concentration throughout pregnancy, with a significant decrease in GW35 ($p < 0.05$) compared to baseline (Figure 3). On the contrary, a 10%, 36%, and 68% increase in plasma concentration were reported by Westin et al. (2017) during trimesters 1–3, respectively. Other studies have identified a similar decrease to that reported here (M.P. Freeman et al., 2008) (D.K. Sit et al., 2008);

< 10 ng/mL and **> 75 ng/mL** charts arranged in rows labeled EM, PM, UM. Each chart plots Percentage of subjects vs Daily dose (mg) for Trimester 1, Trimester 2, Trimester 3.

FIGURE 6 Dose optimization of sertraline during pregnancy in CYP 2C19 phenotyped subjects

however, Westin et al. (2017) included individualized sample data throughout gestation rather than a central tendency without variance (D.K. Sit et al., 2008), missing patient sample data throughout the study or utilizing poor sample sizes (M.P. Freeman et al., 2008). Nonetheless, to further examine the reported disparity in clinical observations, we assessed changes in trough plasma concentrations and intrinsic clearance as a result of population variability in the phenotypes of one of the primary CYP isozyme responsible for sertraline metabolism, namely, CYP 2C19. In all tested phenotypes, the intrinsic clearance decreased throughout pregnancy, mirroring decreases in CYP 2C19 activity, the largest significant difference in clearance being noticed in trimester 3 (Supplementary Materials: Section 4 Table S3).

This decrease in clearance was expected to increase sertraline trough plasma concentrations, as observed by Westin et al. (2017). On the contrary, trough plasma concentrations for EMs and UMs decreased during gestation, with the greatest significant decrease occurring in trimester 3 (Figure 6), which concurred with a range of other reports (M.P. Freeman et al., 2008; Schoretsanitis et al., 2020; D.K. Sit et al., 2008; Tracy et al., 2005; Ververs et al., 2009). This

decrease has been associated with an increase in the key female hormones estradiol and progesterone throughout pregnancy, with concentrations reaching up to 100 nM and 1 μM for estradiol and progesterone, respectively, at term. These levels are significantly greater than those during menstruation (<50 nM) (Cunningham et al., 2014; Holinka, et al., 2008). Such female hormones are known to be activators for basic helix-loop-helix transcription factors (e.g., aryl hydrocarbon receptor; AhR) or nuclear hormone transcriptional regulators (constitutive androstane receptor, CAR; pregnane X receptor, PXR; estrogen receptor, ER), which contribute to the induction of a variety of CYP isoforms and enhanced drug clearances (H. Chen et al., 2009; Jeong et al., 2008). However, the metabolic breakdown of sertraline is complicated, and includes CYPs 2B6, 2C9, 2C19, 2D6, and 3A4. The contribution of each isozyme has proven difficult to determine in vivo; however, the variable up- or down-regulation of CYP isozyme expression during gestation (Abduljalil & Badhan, 2020) may contribute to the disparity observed in some studies (Westin et al., 2017). For example, the approximate 2-fold decrease in 2C19 activity coupled with approximately 2-fold increase in 2B6 activity by trimester 3 may negate the overall impact of

each pathway, in preference to changes in other physiological factors such as increases in total body water. Furthermore, the concomitant decrease in albumin is likely to cause the observed increase in sertraline plasma unbound fraction, and hence increase the volume of distribution, extending the half-life and reducing sertraline plasma levels. To confirm this, a global sensitivity analysis (GSA) was implemented to examine the combined influence of albumin levels, CYPs 2C19 and 2B6 abundance on C_{max}, AUC, clearance (Cl), and Vss (Supplementary Materials: Section 6) within the model. The resulting model sensitivity rankings (Supplementary Materials: Section 6 Table S5) confirmed the sensitivity of the model to changes in human serum albumin levels throughout gestation, and primarily in trimester 3 (Supplementary Materials: Section 6 Table S6). Given that sertraline is highly protein-bound, the decrease in albumin during pregnancy would be a significant driver for reduced plasma levels and an extension of the half-life (Little & Gynecology, 1999), potentially more so that the impact of CYP isozyme gestational changes.

At present, there is a paucity of studies exploring the impact of CYP 2C19 phenotypes on sertraline levels during pregnancy. A recent dosing guideline for sertraline that considered CYP 2C19 phenotypes has been published (Hicks et al., 2015). However, it is not clear whether the proposed guidelines are relevant to pregnant women. Given the importance of the phenotype of the subject on gestational sertraline levels, we next examined the changes in the trough levels in relation to the therapeutic range of sertraline under a standard 50-mg daily dosage of sertraline (Bråten et al., 2020). As expected, the UM phenotypes demonstrated the largest number of subjects below 10 ng/ml (Supplementary Materials: Section 5 Table S4), whereas for the PM group, this was predicted to be in the range of 24–31%.

Finally, for all phenotypes (EM, PM, and UM), dose titrations were required to daily doses that were typically in excess of the 50-mg dose throughout pregnancy. For EM and UM, a dose escalation to 100–150 mg daily is suggested to be optimal through pregnancy. For PM, a dose of 50 mg during the first trimester followed by a dose increase in trimesters 2 and 3 to 100 mg is suggested to be optimal. Furthermore, the doses suggested in this study are within the range clinically utilized and significantly below the known toxicity range in adults (>4000 mg/daily) (Lau & Horowitz, 1996). The return of maternal sertraline plasma levels would be needed postnatally, and although this is not possible to simulate within Simcyp, tapering the dose of sertraline by 50 mg per 5–7 days is recommended to avoid withdrawal syndrome (Shelton & Richard, 2001). Furthermore, although there is very little published studies reporting pharmacodynamic changes during pregnancy for sertraline, the current approaches for the studies during pregnancy focus primarily on the clinician's role in the dose titration based on empirical changes in the psychiatric state of the patient (Ornoy & Koren, 2019). In addition, although clinicians routinely monitor drug pharmacodynamics by directly measuring physiological indices of therapeutic responses, the link between (unbound) plasma levels and clinical response is not well established for sertraline (Bergink et al., 2011; Cox et al., 1987; Sachs et al., 2002). Further, any attempt to relate unbound levels to a pharmacodynamic effect would need to further consider that the

resultant central effects would be governed by the blood–brain barrier, which acts as a permeability barrier to any resultant central effects on reuptake of monoamines into the presynaptic neurons. Further work is needed to address the reductions in sertraline plasma concentration through gestation on the resultant maternal pharmacodynamic effects on mood stability, in order to fully translate the results presented in this article to clinical practice.

A key benefit of the pregnancy PBPK approach highlighted in our study is the ability to incorporate key gestational changes in the physiology of the mother; for example, the highlighted reduction in plasma albumin and increase in maternal volume, which can be coupled with a mechanistic description of the activities of a metabolizing enzyme to enable disentangling what would otherwise be clinically complicated relationships.

5 | CONCLUSION

Any decision to withdraw or continue with antidepressant therapy perinatally is challenging for both maternal and fetal health. A key paradigm is the balance between the benefit of continuing treatment and the risk drug-related toxicity to the developing embryo/fetus.

Confounding treatment during gestation are longitudinal maternal physiological alternations that alter the requirements for dosing. Furthermore, the susceptibility of CYP 2C19 to polymorphisms only increases the complexity in prescribing decisions.

Our results demonstrated that dose titrations are required throughout pregnancy, with UM subjects being of concern and requiring at least double the standard dose by trimester 3, to support ongoing maintenance of plasma sertraline concentrations to within the therapeutic range.

This study has highlighted a key role for the use of pharmacokinetics to allow pragmatic exploration of dosing regimens within a perinatal setting, to support the reduction in risk of treatment relapse due to inappropriate dosing.

ORCID

Raj K. S. Badhan https://orcid.org/0000-0002-0904-9324

REFERENCES

Abduljalil, K., & Badhan, R. K. S. (2020). Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models. *Journal of Pharmacokinetics and Pharmacodynamics*, 47(4), 319–340. https://doi.org/10.1007/s10928-020-09698-w

Abduljalil, K., Furness, P., Johnson, T. N., Rostami-Hodjegan, A., & Soltani, H. (2012). Anatomical, physiological and metabolic changes with gestational age during normal pregnancy. *Clinical Pharmacokinetics*, 51(6), 365–396. https://doi.org/10.2165/11597440-000000000-00000

Alfaro, C. L., Lam, Y. W. F., Simpson, J., & Ereshefsky, L. (2000). CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations. *The Journal of Clinical Pharmacology*, 40(1), 58–66. https://doi.org/10.1177/00912700022008702

Almurjan, A., Macfarlane, H., & Badhan, R. K. S. (2020). Precision dosing-based optimization of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolizers: A virtual clinical trial pharmacokinetics study. *Journal of Pharmacy and Pharmacology*, 72(8), 1049–1060. https://doi.org/10.1111/jphp.13281

Bérard, A., Zhao, J.-P., & Sheehy, O. (2017). Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: An updated analysis of the quebec pregnancy cohort. *BMJ open*, 7(1), e013372–e013372. https://doi.org/10.1136/bmjopen-2016-013372

Bergink, V., Kooistra, L., Lambregtse-van den Berg, M. P., Wijnen, H., Bunevicius, R., van Baar, A., & Pop, V. (2011). Validation of the edinburgh depression scale during pregnancy. *Journal of Psychosomatic Research*, 70(4), 385–389. https://doi.org/10.1016/j.jpsychores.2010.07.008

Bråten, L. S., Haslemo, T., Jukic, M. M., Ingelman-Sundberg, M., Molden, E., & Kringen, M. K. (2020). Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. *Neuropsychopharmacol.*, 45(3), 570–576. https://doi.org/10.1038/s41386-019-0554-x

Byatt, N., Deligiannidis, K. M., & Freeman, M. P. (2013). Antidepressant use in pregnancy: A critical review focused on risks and controversies. *Acta Psychiatrica Scandinavica*, 127(2), 94–114. https://doi.org/10.1111/acps.12042

Byatt, N., Xiao, R. S., Dinh, K. H., & Waring, M. E. (2016). Mental health care use in relation to depressive symptoms among pregnant women in the USA. *Arch Womens Ment Health*, 19(1), 187–191. https://doi.org/10.1007/s00737-015-0524-1

Chen, H., Yang, K., Choi, S., Fischer, J. H., & Jeong, H. (2009). Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17β-estradiol: A potential mechanism of increased lamotrigine elimination in pregnancy. *Drug Metabolism & Disposition*, 37(9), 1841–1847. https://doi.org/10.1124/dmd.109.026609

Chen, X., Duan, X., Dai, X., & Zhong, D. (2006). Development and validation of a liquid chromatographic/tandem mass spectrometric method for the determination of sertraline in human plasma. *Rapid Communications in Mass Spectrometry*, 20, 2483–2489

Colvin, L., Slack-Smith, L., Stanley, F. J., & Bower, C. (2011). Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 91(3), 142–152.

Cox, J. L., Holden, J. M., & Sagovsky, R. (1987). Detection of postnatal depression. *British Journal of Psychiatry*, 150, 782–786. https://doi.org/10.1192/bjp.150.6.782

Cunningham, F., Leveno, K., Bloom, S., Spong, C. Y., & Dashe, J. (2014). *Williams obstetrics* 24e. Mcgraw-hill.

De Sousa Mendes, M., Hirt, D., Urien, S., Valade, E., Bouazza, N., Foissac, F., Blanche, S., Treluyer, J.-M., & Benaboud, S. (2015). Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. *British Journal of Clinical Pharmacology*, 80(5), 1031–1041. https://doi.org/10.1111/bcp.12685

Djebli, N., Fabre, D., Boulenc, X., Fabre, G., Sultan, E., & Hurbin, F. (2015). Physiologically based pharmacokinetic modeling for sequential metabolism: Effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics. *Drug Metabolism & Disposition*, 43(4), 510–522. https://doi.org/10.1124/dmd.114.062596

Edginton, A. N., Schmitt, W., & Willmann, S. (2006). Development and evaluation of a generic physiologically based pharmacokinetic model for children. *Clinical Pharmacokinetics*, 45(10), 1013–1034. https://doi.org/10.2165/00003088-200645100-00005

Fisher, J., Cabral de Mello, M., Patel, V., Rahman, A., Tran, T., Holton, S., & Holmes, W. (2012). Prevalence and determinants of common perinatal mental disorders in women in low- and lower-middle-income countries: A systematic review. *Bulletin of the World Health Organization*, 90(2), 139–149H. https://doi.org/10.2471/BLT.11.091850

Freeman, M. P., Nolan, P. E., Jr, Davis, M. F., Anthony, M., Fried, K., Fankhauser, M., Woosley, R. L., & Moreno, F. (2008). Pharmacokinetics of sertraline across pregnancy and postpartum. *Journal of Clinical Psychopharmacology*, 28(6), 646–653. https://doi.org/10.1097/JCP.0b013e31818d2048

Gaynes, B. N., Gavin, N., Meltzer-Brody, S., Lohr, K. N., Swinson, T., Gartlehner, G., & Miller, W. C. (2005). Perinatal depression: Prevalence, screening accuracy, and screening outcomes. *Evidence Report - Technology Assessment*, 119, 1–8.

Geier, M. L., Hills, N., Gonzales, M., Tum, K., & Finley, P. R. (2015). Detection and treatment rates for perinatal depression in a state Medicaid population. *CNS Spectrums*, 20(1), 11–19. https://doi.org/10.1017/s1092852914000510

George, B., Lumen, A., Nguyen, C., Wesley, B., Wang, J., Beitz, J., & Crentsil, V. (2020). Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy. *Npj Syst Biol Appl*, 6(1), 36. https://doi.org/10.1038/s41540-020-00157-3

Ginsberg, G., Hattis, D., Russ, A., & Sonawane, B. (2004). Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: Implications for assessing children's risks from environmental agents. *Journal of Toxicology and Environmental Health, Part A*, 67(4), 297–329. https://doi.org/10.1080/15287390490273550

Gong, J., Iacono, L., Iyer, R. A., Humphreys, W. G., & Zheng, M. (2018). Physiologically-based pharmacokinetic modeling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data. *British Journal of Clinical Pharmacology*, 84(6), 1335–1345. https://doi.org/10.1111/bcp.13565

Hicks, J., Bishop, J., Sangkuhl, K., Müller, D., Ji, Y., Leckband, S., Leeder, J., Graham, R., Chiulli, D., LLerena, A., Skaar, T., Scott, S., Stingl, J., Klein, T., Caudle, K., Gaedigk, A., & Clinical Pharmacogenetics Implementation, C. (2015). Clinical Pharmacogenetics implementation Consortium (CPIC) guideline forCYP2D6andCYP2C19Genotypes and dosing of selective serotonin reuptake inhibitors. *Clinical Pharmacology & Therapeutics*, 98(2), 127–134. https://doi.org/10.1002/cpt.147

Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., Gründer, G., Haen, E., Havemann-Reinecke, U., Hefner, G., Helmer, R., Janssen, G., Jaquenoud, E., Laux, G., Messer, T., Mössner, R., Müller, M., Paulzen, M., Pfuhlmann, B., Riederer, P., Saria, A., Schoppek, B., Schoretsanitis, G., Schwarz, M., Gracia, M., Stegmann, B., Steimer, W., Stingl, J., Uhr, M., Ulrich, S., Unterecker, S., Waschgler, R., Zernig, G., Zurek, G., & Baumann, P. (2018). Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. *Pharmacopsychiatry*, 51(01/02), 9–62.

Högstedt, S., Lindberg, B., Peng, D. R., Regårdh, C.-G., & Rane, A. (1985). Pregnancy-induced increase in metoprolol metabolism. *Clinical Pharmacology & Therapeutics*, 37(6), 688–692.

Högstedt, S., Lindberg, B., & Rane, A. (1983). Increased oral clearance of metoprolol in pregnancy. *European Journal of Clinical Pharmacology*, 24(2), 217–220.

Holinka, C. F., Diczfalusy, E., & Bennink, H. J. T. C.(2008). Estetrol: a unique steroid in human pregnancy. *The Journal of Steroid Biochemistry and Molecular Biology*, 110(1–2), 138–143.

Hostetter, A., Stowe, Z. N., Strader, J. R., Jr, McLaughlin, E., & Llewellyn, A. (2000). Dose of selective serotonin uptake inhibitors across pregnancy: Clinical implications. *Depression and Anxiety*, 11(2), 51–57.

Isoherranen, N., & Thummel, K. E. (2013). Drug metabolism and transport during pregnancy: How does drug disposition change during pregnancy and what are the mechanisms that cause such changes? *Drug Metabolism & Disposition*, 41(2), 256–262. https://doi.org/10.1124/dmd.112.050245

Jeong, H., Choi, S., Song, J. W., Chen, H., & Fischer, J. H. (2008). Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. *Xenobiotica*, 38(1), 62–75. https://doi.org/10.1080/00498250701744633

Jogiraju, V. K., Avvari, S., Gollen, R., & Taft, D. R. (2017). Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations. *Biopharmaceutics & Drug Disposition*, 38(7), 426–438. https://doi.org/10.1002/bdd.2081

Ke, A. B., Greupink, R., & Abduljalil, K. (2018). Drug dosing in pregnant women: Challenges and opportunities in using physiologically based pharmacokinetic modeling and simulations. *CPT: Pharmacometrics & Systems Pharmacology*, 7(2), 103–110. https://doi.org/10.1002/psp4.12274

Kim, J. J., & Silver, R. K. (2016). Perinatal suicide associated with depression diagnosis and absence of active treatment in 15-year UK national inquiry. *Evidence-Based Mental Health*, 19(4), 122. https://doi.org/10.1136/eb-2016-102373

Kim, K. M., Jung, B. H., Choi, M. H., Woo, J. S., Paeng, K. J., & Chung, B. C. (2002). Rapid and sensitive determination of sertraline in human plasma using gas chromatography-mass spectrometry. *Journal of chromatography. B, Analytical technologies in the biomedical and life sciences*, 769(2), 333–339. https://doi.org/10.1016/s1570-0232(02)00027-2

Koh, K. H., Jurkovic, S., Yang, K., Choi, S.-Y., Jung, J. W., Kim, K. P., Zhang, W., & Jeong, H. (2012). Estradiol induces cytochrome P450 2B6 expression at high concentrations: Implication in estrogen-mediated gene regulation in pregnancy. *Biochemical Pharmacology*, 84(1), 93–103. https://doi.org/10.1016/j.bcp.2012.03.016

Kosel, B. W., Beckerman, K. P., Hayashi, S., Homma, M., & Aweeka, F. T. (2003). Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. *Aids*, 17(8), 1195–1199.

Lam, Y. W. F., Gaedigk, A., Ereshefsky, L., Alfaro, C. L., & Simpson, J. (2002). CYP2D6 inhibition by selective serotonin reuptake inhibitors: Analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 22(8), 1001–1006. https://doi.org/10.1592/phco.22.12.1001.33603

Lau, G. T., & Horowitz, B. Z. (1996). Sertraline overdose. *Academic Emergency Medicine*, 3(2), 132–136. https://doi.org/10.1111/j.1553-2712.1996.tb03400.x

Little, B., & Gynecology (1999). Pharmacokinetics during pregnancy: Evidence-based maternal dose formulation. *Obstetrics & Gynecology*, 93(5), 858–868.

Lu, G., Abduljalil, K., Jamei, M., N. Johnson, T., Soltani, H., & Rostami-Hodjegan, A. (2012). Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: Achievements and shortcomings. *Cdm*, 13(6), 695–720. https://doi.org/10.2174/138920012800840374

Mauri, M. C., Fiorentini, A., Cerveri, G., Volonteri, L. S., Regispani, F., Malvini, L., Boscati, L., Baido, R. L., & Invernizzi, G. (2003). Long-term efficacy and therapeutic drug monitoring of sertraline in major depression. *Human Psychopharmacology: Clinical and Experimental*, 18(5), 385–388. https://doi.org/10.1002/hup.502

McAllister-Williams, R. H., Baldwin, D. S., Cantwell, R., Easter, A., Gilvarry, E., Glover, V., Green, L., Gregoire, A., Howard, L. M., Jones, I., Khalifeh, H., Lingford-Hughes, A., McDonald, E., Micali, N., Pariante, C. M., Peters, L., Roberts, A., Smith, N. C., Taylor, D., Wieck, A., Yates,

L. M., & Young, A. H. (2017). British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. *Journal of Psychopharmacology*, 31(5), 519–552. https://doi.org/10.1177/0269881117699361

McGready, R., Stepniewska, K., Edstein, M. D., Cho, T., Gilveray, G., Looareesuwan, S., White, N. J., & Nosten, F. (2003). The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. *European Journal of Clinical Pharmacology*, 59(7), 545–552.

McGready, R., Stepniewska, K., Seaton, E., Cho, T., Cho, D., Ginsberg, A., Edstein, M. D., Ashley, E., Looareesuwan, S., White, N. J., & Nosten, F. (2003). Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. *European Journal of Clinical Pharmacology*, 59(7), 553–557.

Niyomnaitham, S., Chatsiricharoenkul, S., Sathirakul, K., Pongnarin, P., & Kongpatanakul, S. (2009). Bioequivalence study of 50 mg sertraline tablets in healthy Thai volunteers. *Medical Journal of the Medical Association of Thailand*, 92(9), 1229–1233.

Nordeng, H., van Gelder, M. M. H. J., Spigset, O., Koren, G., Einarson, A., & Eberhard-Gran, M. (2012). Pregnancy outcome after exposure to antidepressants and the role of maternal depression. *Journal of clinical psychopharmacology*, 32(2), 186–194.

Obach, R. S., Cox, L. M., & Tremaine, L. M. (2005). Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study. *Drug Metabolism & Disposition*, 33(2), 262–270. https://doi.org/10.1124/dmd.104.002428

Oberlander, T. F., Warburton, W., Misri, S., Riggs, W., Aghajanian, J., & Hertzman, C. (2008). Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. *Birth Defects Research B*, 83(1), 68–76.

Olafuyi, O., & Badhan, R. K. S. (2019). Dose optimization of chloroquine by pharmacokinetic modeling during pregnancy for the treatment of zika virus infection. *Journal of Pharmaceutical Sciences*, 108(1), 661–673. https://doi.org/10.1016/j.xphs.2018.10.056

Ornoy, A., & Koren, G. (2019). SSRIs and SNRIs (SRI) in pregnancy: Effects on the course of pregnancy and the offspring: How far are we from having all the answers? *Ijms*, 20(10), 2370.

Pae, C.-U., & Patkar, A. A. (2007). Paroxetine: Current status in psychiatry. *Expert Review of Neurotherapeutics*, 7(2), 107–120. https://doi.org/10.1586/14737175.7.2.107

Parrott, N., Davies, B., Hoffmann, G., Koerner, A., Lave, T., Prinssen, E., Theogaraj, E., & Singer, T. (2011). Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. *Clinical Pharmacokinetics*, 50(9), 613–623. https://doi.org/10.2165/11592640-000000000-00000

Prevost, R. R., Akl, S. A., Whybrew, W. D., & Sibai, B. M. (1992). Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 12(3), 174–177.

Ramos, É., Oraichi, D., Rey, É., Blais, L., & Bérard, A. (2007). Prevalence and predictors of antidepressant use in a cohort of pregnant women. *BJOG: An International Journal of Obstetrics and Gynaecology*, 114(9), 1055–1064.

Reis, M., & Källén, B. (2010). Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. *Psychological Medicine*, 40(10), 1723–1733. https://doi.org/10.1017/S0033291709992194

Ronfeld, R. A., Tremaine, L. M., & Wilner, K. D. (1997). Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. *Clinical Pharmacokinetics*, 32(Suppl 1), 22–30. https://doi.org/10.2165/00003088-199700321-00004

Sachs, G. S., Guille, C., & McMurrich, S. L. (2002). A clinical monitoring form for mood disorders. *Bipolar Disorders*, *4*(5), 323–327. https://doi.org/10.1034/j.1399-5618.2002.01195.x

Saiz-Rodríguez, M., Belmonte, C., Román, M., Ochoa, D., Koller, D., Talegón, M., Ovejero-Benito, M. C., López-Rodríguez, R., Cabaleiro, T., & Abad-Santos, F. (2018). Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers. *Basic and Clinical Pharmacology and Toxicology*, *122*(5), 501–511. https://doi.org/10.1111/bcpt.12938

Saletu, B., Grunberger, J., & Linzmayer, L. (1986). On central effects of serotonin re-uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidine. *Journal of Neural Transmission*, *67*(3–4), 241–266. https://doi.org/10.1007/bf01243351

Schoretsanitis, G., Spigset, O., Stingl, J. C., Deligiannidis, K. M., Paulzen, M., & Westin, A. A. (2020). The impact of pregnancy on the pharmacokinetics of antidepressants: A systematic critical review and meta-analysis. *Expert Opinion on Drug Metabolism and Toxicology*, *16*(5), 431–440. https://doi.org/10.1080/17425255.2020.1750598

Shelton, R. C. (2001). Steps following attainment of remission. *Primary Care Companion to the Journal of Clinical Psychiatry*, *03*, 168–174.

Sit, D.K., Perel, J. M., Helsel, J. C., & Wisner, K. L. (2008). Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. *Journal of Clinical Psychiatry*, *69*(4), 652–658. https://doi.org/10.4088/jcp.v69n0419

Templeton, I., Chen, Y., Mao, J., Lin, J., Yu, H., Peters, S., Shebley, M., & Varma, M. (2016). Quantitative prediction of drug-drug interactions involving inhibitory metabolites in drug development: How can physiologically based pharmacokinetic modeling help? *CPT: Pharmacometrics & Systems Pharmacology*, *5*(10), 505–515. https://doi.org/10.1002/psp4.12110

Tracy, T. S., Venkataramanan, R., Glover, D. D., Caritis, S. N., & National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units (2005). Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. *American Journal of Obstetrics and Gynecology*, *192*(2), 633–639. https://doi.org/10.1016/j.ajog.2004.08.030

U.S. Food and Drug Administration. (2012). *Summary minutes of the advisory committee for pharmaceutical science and clinical pharmacology*. Retrieved from https://wayback.archive-it.org/7993/20170403224110/https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/ucm286697.htm

Ververs, F. F. T., Voorbij, H. A. M., Zwarts, P., Belitser, S. V., Egberts, T. C. G., Visser, G. H. A., & Schobben, A. F. A. M. (2009). Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. *Clinical Pharmacokinetics*, *48*(10), 677–683. https://doi.org/10.2165/11318050-000000000-00000

Vigod, S. N., Wilson, C. A., & Howard, L. M. (2016). Depression in pregnancy. *BMJ*, *352*, i1547. https://doi.org/10.1136/bmj.i1547

Wadelius, M., Darj, E., Frenne, G., & Rane, A. (1997). Induction of CYP2D6 in pregnancy. *Clinical Pharmacology & Therapeutics*, *62*(4), 400–407. https://doi.org/10.1016/S0009-9236(97)90118-1

Ward, S., Helsby, N., Skjelbo, E., Brosen, K., Gram, L., & Breckenridge, A. (1991). The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism-a panel study. *British Journal of Clinical Pharmacology*, *31*(6), 689–692.

Westin, A. A., Brekke, M., Molden, E., Skogvoll, E., Castberg, I., & Spigset, O. (2018). Treatment with antipsychotics in pregnancy: Changes in drug disposition. *Clinical Pharmacology & Therapeutics*, *103*(3), 477–484. https://doi.org/10.1002/cpt.770

Westin, A. A., Brekke, M., Molden, E., Skogvoll, E., & Spigset, O. (2017). Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. *PloS One*, *12*(7), e0181082. https://doi.org/10.1371/journal.pone.0181082

World Health Organization (2008). *The global burden of disease: 2004 update*.

Zakiyah, N., Ter Heijne, L. F., Bos, J. H., Hak, E., Postma, M. J., & Schuiling-Veninga, C. C. M. (2018). Antidepressant use during pregnancy and the risk of developing gestational hypertension: A retrospective cohort study. *BMC Pregnancy and Childbirth*, *18*(1), 187. https://doi.org/10.1186/s12884-018-1825-y

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.